Christopher Campen, PharmD BCOP

Senior Medical Science Liaison
Janssen Medical Affairs

Poster(s):

• JL1013E: First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The GLOW Study
  Saturday, October 22, 2022

  10:00 AM – 11:00 AM ET